AROMA-BIT
23.7.2019 03:32:07 CEST | Business Wire | Press release
Aroma Bit launched a new subsidiary to develop the next generation smell sensor based on silicon CMOS sensor substrate that are ultra-compact, high resolution and low cost. The technology is realized by applying Aroma Bit developed smell sensor receptor membrane technology to ultra-sensitive silicon CMOS based ion imaging sensor technology developed by professor Kazuaki Sawada at Toyohashi University of Technology and associated companies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190722005004/en/
Aroma Bit: http://www.aromabit.com
Realizing smartphone embeddable smell sensor with dog nose equivalent ultra-high resolution smell sensor on only 1 millimeter square silicon die size
Aroma Bit has developed and are currently selling a compact smell sensor that employs QCM or Quartz Crystal Microbalance type sensor substrate, which demonstrates ultra-high sensitivity in the sensor market. However, further size reduction, cost reduction to meet high volume application market, such as smartphone, was challenging with conventional QCM type smell sensor.
With the newly developed silicon CMOS type smell sensor, ultra-compact, high smell resolution and low cost can be realized, to be embedded to system such as smartphone or IoT devices. For instance, it is expected that resolution equivalent to dog nose’s resolution (roughly 1,200 receptors) within 1mm die size can be achieved using the new type of sensor substrate.
With new addition of sensor substrate technology, Aroma Bit now holds two types of sensor substrate technology line up: (1) conventional and yet ultra-high sensitivity QCM type sensor substrate technology, and (2) ultra-high resolution, ultra-compact, low cost silicon CMOS type sensor substrate technology. Combined, highly competitive sensor technology portfolio is realized in two key performance for smell sensor, namely, sensor sensitivity and smell resolution. As a result, the addition of the new sensor is expected to further enhances Aroma Bit’s technology competitive advantage against its competitors in the compact smell sensor space.
Aroma Bit is currently also accelerating its development of digital smell database or smell big-data based on its hardware competitive advantage. Sensor hardware and smell database together, Aroma Bit is committed to retain its top-position in growing digital olfactory market, thereby realizing Aroma Bit’s vision “to realize a better world by visualizing the world of smell/aroma through odor imaging technology.”
New subsidiary certified as the first Toyohashi University of Technology University- Launched Venture Company
The new developed subsidiary, Aroma Bit Silicon Sensor Technology, Inc., is certified as the first Toyohashi University of Technology certified University-Launch Venture Company.
While University-Launched Venture company is on the rise in Japan, there is limited successful case leading to industrialization, due to factors such as lack of intellectual property conflict among large companies interest, skill set mismatch on researcher as entrepreneurs, among others.
In this particular Industry-academia collaboration case, the chance to commercialize technology is expected to increase by assigning venture company a role to drive business development of the technology developed jointly with university.
Background:
Aroma Bit succeeded in developing next generation smell sensor based on silicon CMOS sensor substrate that are ultra-compact and high resolution by applying Aroma Bit developed smell sensor receptor membrane technology to ultra-sensitive silicon CMOS based ion imaging sensor technology developed by professor Kazuaki Sawada at Toyohashi University of Technology.
In 2017, Toyohashi Technology of University, Toyohashi Sensor Kyogikai Corporation, Hamamatsu Photonics K.K., Toho Technology Corporation, Nippon Chemi-con Corporation and Aroma Bit together formed private Consortium COSCo (CMOS Odor Sensor Consortium). In 2018, COSCo consortium released working prototypes such as Kaori-Camera (Aroma Camera) and i-sniffer.
In the interest to aggregate the achievement from COSCo consortium and further accelerate development and industrialization, Aroma Bit Silicon Sensor Technology, Inc. (Hereafter, “ABSST”) is founded as Aroma Bit’s subsidiary.
Going forward, ABSST is committed to develop the silicon CMOS type next generation smell sensor that are ultra-high resolution, ultra-compact and low-cost embeddable to smartphone and IoT Devices.
New Subsidiary Company Profile |
|
Name of company: |
Aroma Bit Silicon Sensor Technology Inc. (ABSST) |
Date of Registration: |
June 28th, 2019 |
Paid-in-Capital: |
10 Million JPY [Aroma Bit, Inc. Subsidiary] |
Business Profile: |
Planning, Development, Manufacturing and Sales of silicon CMOS based next generation smell, gas sensor, and other related business |
Representative Management: |
Representative Director & CEO Shunichiro Kuroki [Current Representative Director & CEO of Aroma Bit, Inc.] |
Address: |
E205 KSP 3-2-1 Sakado, Takatsu-ku, Kawasaki-city, Kanagawa 213-0012 [Aroma Bit Kawasaki Lab] |
Corporate URL: |
|
Contact: |
Email: info@aromabitsst.com
|
About Aroma Bit |
Aroma Bit develops, produces and sells electronic equipments and systems including compact odor imaging sensors. |
[Corporate summary] |
|
Name: |
Aroma Bit, Inc. |
Address: |
Sagami Building 2F 7-13-6 Ginza, Chuo-ku, Tokyo |
Representative: |
Representative Director & CEO Sunichiro Kuroki |
Established: |
February, 2014 |
Business: |
- Development, Production and Sales of electronic equipments and systems including compact odor imaging sensors. |
- Development, Production and Sales of innovative services using the Sensor products. |
|
|
- Other business related to the above. |
Corporate URL: |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20190722005004/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
